edelfosine has been researched along with Leukemic Infiltration in 1 studies
edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.
Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This provided an increase in relative oral bioavailability of 1500% after a single oral administration of drug-loaded LNs, maintaining edelfosine plasma levels over 7 days in contrast to a single oral administration of edelfosine solution, which presented a relative oral bioavailability of 10%." | 5.38 | Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. ( Blanco-Prieto, MJ; Campanero, MA; de la Iglesia-Vicente, J; Estella-Hermoso de Mendoza, A; Lana, H; Mollinedo, F; Villa-Pulgarin, JA, 2012) |
| "This provided an increase in relative oral bioavailability of 1500% after a single oral administration of drug-loaded LNs, maintaining edelfosine plasma levels over 7 days in contrast to a single oral administration of edelfosine solution, which presented a relative oral bioavailability of 10%." | 1.38 | Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. ( Blanco-Prieto, MJ; Campanero, MA; de la Iglesia-Vicente, J; Estella-Hermoso de Mendoza, A; Lana, H; Mollinedo, F; Villa-Pulgarin, JA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Estella-Hermoso de Mendoza, A | 1 |
| Campanero, MA | 1 |
| Lana, H | 1 |
| Villa-Pulgarin, JA | 1 |
| de la Iglesia-Vicente, J | 1 |
| Mollinedo, F | 1 |
| Blanco-Prieto, MJ | 1 |
1 other study available for edelfosine and Leukemic Infiltration
| Article | Year |
|---|---|
Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles.
Topics: Animals; Diglycerides; Fatty Acids; Humans; Leukemic Infiltration; Lymph Nodes; Lymphoma; Mice; Nano | 2012 |